These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8100664)

  • 21. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.
    Shearer GM; Pinto LA; Clerici M
    Immunol Today; 1999 Feb; 20(2):66-71. PubMed ID: 10098324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Macaque models for AIDS vaccine development.
    Johnson RP
    Curr Opin Immunol; 1996 Aug; 8(4):554-60. PubMed ID: 8794019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Virological and immunological bases for HIV-1 vaccine design].
    Yamamoto H; Matano T
    Uirusu; 2007 Dec; 57(2):133-9. PubMed ID: 18357751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of protection against simian immunodeficiency virus infection.
    Johnson RP
    Vaccine; 2002 May; 20(15):1985-7. PubMed ID: 11983259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
    J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency Virus (SHIV(89.6)P).
    Kumar A; Lifson JD; Li Z; Jia F; Mukherjee S; Adany I; Liu Z; Piatak M; Sheffer D; McClure HM; Narayan O
    Virology; 2001 Jan; 279(1):241-56. PubMed ID: 11145906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative HIV vaccine strategies.
    Lehner T; Shearer GM
    Science; 2002 Aug; 297(5585):1276-7. PubMed ID: 12194176
    [No Abstract]   [Full Text] [Related]  

  • 28. AIDS vaccine models: challenging challenge viruses.
    Feinberg MB; Moore JP
    Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
    [No Abstract]   [Full Text] [Related]  

  • 29. SIV vaccines: current status. The role of the SIV-macaque model in AIDS research.
    Gardner M
    Vaccine; 1991 Nov; 9(11):787-91. PubMed ID: 1759500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SIV and FIV vaccine studies at UC Davis: 1991 update.
    Gardner M; Yamamoto J; Marthas M; Miller C; Jennings M; Rosenthal A; Luciw P; Planelles V; Yilma T; Giavedoni L
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1495-8. PubMed ID: 1334682
    [No Abstract]   [Full Text] [Related]  

  • 32. Summary of the SIV Working Group.
    Schultz AM
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1439-40. PubMed ID: 1466977
    [No Abstract]   [Full Text] [Related]  

  • 33. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus.
    Cranage MP; Polyanskaya N; McBride B; Cook N; Ashworth LA; Dennis M; Baskerville A; Greenaway PJ; Corcoran T; Kitchin P
    AIDS Res Hum Retroviruses; 1993 Jan; 9(1):13-22. PubMed ID: 8427714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 25 years of HIV research! ... and what about a vaccine?
    Appay V
    Eur J Immunol; 2009 Aug; 39(8):1999-2003. PubMed ID: 19672891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA vaccination for HIV-1 and SIV.
    Barouch DH; Letvin NL
    Intervirology; 2000; 43(4-6):282-7. PubMed ID: 11251383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine.
    Hirsch VM; Goldstein S; Hynes NA; Elkins WR; London WT; Zack PM; Montefiori D; Johnson PR
    J Infect Dis; 1994 Jul; 170(1):51-9. PubMed ID: 8014520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AIDS vaccines show promise in primates.
    Clin Infect Dis; 2001 Oct; 33(7):i-ii. PubMed ID: 11592258
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytotoxic T lymphocytes in AIDS pathogenesis: lessons to be learned from the macaque model of simian immunodeficiency virus infection.
    Geretti AM; Hulskotte E; Osterhaus AD
    J Gen Virol; 1998 Mar; 79 ( Pt 3)():415-21. PubMed ID: 9519818
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.